New agents in the treatment of childhood leukemias and myelodysplastic syndromes.
New agents in the treatment of childhood leukemias and myelodysplastic syndromes.
复制标题
DOI：
10.1007/s11912-005-0003-3
复制
发表时间：
2005-11-01
影响因子：
4.7
通讯作者：
Corey, Seth J
中科院分区：
文献类型：
--
作者：
Corey, Seth J
复发或难治性白血病仍然是儿科肿瘤最常见的治疗问题。尤其具有挑战性的是干细胞移植后复发的患者。对白血病分子发病机制的深入研究已经产生了一系列新药。这些新药物在击中目标时将更具选择性，因此它们的用途将比传统的细胞毒性药物更狭窄。这些新药物包括全反式维甲酸、吉妥珠单抗、甲磺酸伊马替尼、利妥昔单抗和一系列信号转导抑制剂和治疗性单克隆抗体。其他新药物，如柔红霉素脂质体、peg -天冬酰胺酶或氯法拉滨，是已建立的抗白血病药物的化学修饰。分子谱分析将越来越多地用于指导新药的开发和应用。
Relapsed or refractory leukemia remains the most common therapeutic problem in pediatric oncology. Particularly challenging is the patient who has recurrence following a stem cell transplant. Insights into the molecular pathogenesis of the leukemias have produced an array of new agents. These new agents will be more selective in hitting their targets, and so their use will be more narrowly defined than with classical cytotoxic drugs. These new agents include all-trans retinoic acid, gemtuzumab ozogamicin, imatinib mesylate, rituximab, and a bevy of signal transduction inhibitors and therapeutic monoclonal antibodies. Other new agents, such as liposomal daunorubicin, PEG-asparaginase, or clofarabine, represent chemical modifications of established antileukemic drugs. Increasingly, molecular profiling will be used to guide the development and application of new drugs.